PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Last trade$60.29
Day change-$0.68 (-1.12%)
Day range$58.60 – $61.41
Volume560,844
Market cap$5.09B
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$5.09B
Price / earnings
—
Price / book
-26.64×
Price / sales
4.41×
EV / sales
4.43×
EV / EBITDA
16.47×
Profitability
Earnings per share
-$1.27
Return on assets
-3.3%
Return on equity
55.42%
Dividend yield
0%
Liquidity and leverage
Debt / equity
-2.82×
Current ratio
3.27×
Quick ratio
3.13×
Cash ratio
0.66×
Cash flow
Price / cash flow
485.72×
Price / free cash flow
2,464.29×
Free cash flow
$2.07M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for PTCT, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$357.81M
$360.52M
$272.55M
$164.68M
$211.01M
$178.88M
$1.18B
$213.17M
Cost of revenue
$23.66M
$19.92M
$28.03M
$6.95M
$15.78M
$11.42M
$12.86M
$16.28M
Gross profit
$334.14M
$340.6M
$244.52M
$157.73M
$195.23M
$167.46M
$1.16B
$196.89M
Selling, general and administrative
$80.08M
$80.63M
$86.18M
$96.87M
$84.05M
$85.26M
$80.96M
$84.68M
Research and development
$105.35M
$99.15M
$100.87M
$133.13M
$100.16M
$112.99M
$108.97M
$124.77M
Total operating expenses
$198.03M
$191.62M
$199.56M
$228.28M
$192.21M
$202.41M
$193.81M
$364.98M
Operating income
$136.11M
$148.98M
$44.96M
-$70.55M
$3.02M
-$34.96M
$969.43M
-$168.09M
Interest expense
-$45.87M
-$48.48M
-$49.03M
$0
-$32.59M
-$30.36M
-$34.09M
$0
Income before taxes
-$41.09M
$97.55M
-$2.46M
-$139.08M
-$23.07M
-$71.05M
$929.83M
-$94.7M
Income taxes
$10.61M
$14.05M
$347K
-$4.12M
-$38.97M
-$6.2M
$63.27M
-$28.81M
Net income
-$51.69M
$83.5M
-$2.81M
-$134.97M
$15.9M
-$64.85M
$866.56M
-$65.89M
Net income attributable to common shareholders
-$51.69M
$83.5M
-$2.81M
-$134.97M
$15.9M
-$64.85M
$866.56M
-$65.89M
EBITDA
$152.93M
$164.85M
$61.3M
-$67.92M
$14.6M
-$27.28M
$976.72M
-$4.63M
Basic earnings per share
-$0.62
$1.01
-$0.03
-$1.62
$0.20
-$0.83
$11.09
-$0.85
Diluted earnings per share
-$0.62
$0.92
-$0.03
-$1.33
$0.20
-$0.83
$10.04
-$0.85
Recent news
Company coverage with links to the original publishers.
PTC Therapeutics reported Q3 2026 revenue of $357.81 million, up 69.6% year-over-year and beating consensus estimates by 15.02%. EPS of $0.61 significantly exceeded the $0.17 estimate by 258.82%. However, key product revenues showed mixed results: Emflaza declined 28.7% YoY, Translarna fell 4.3% YoY, while Sephience revenue reached $182 million. The stock has underperformed the broader market with a -2.7% return over the past month and carries a Zacks Rank #3 (Hold) rating.
Liquidia Corporation is expected to report Q3 2026 earnings of $0.77 per share with revenues of $186.63 million, representing significant year-over-year growth. However, the consensus EPS estimate has been revised 84.56% lower over the last 30 days. With a negative Earnings ESP of -1.30% and a Zacks Rank #5 (Strong Sell), the stock does not appear to be a compelling earnings-beat candidate.
The Nasdaq gained 1.05% to 27,477 as tech optimism drove market gains despite rising Treasury yields. The S&P 500 rose 0.66% and the Dow added 0.18%. Key movers included Vaxcyte (up 30% on vaccine success), Genmab (up 11% on lymphoma drug data), and PTC (following a $22.6B buyout offer). Nvidia gained 2.12% amid speculation about reaching a $6 trillion market cap. Investors showed increased appetite for risk following softer-than-expected jobs data, reducing expectations for further Fed rate hikes.
PTC Therapeutics' chief technical operations officer sold 2,464 shares under a routine pre-established trading plan, generating $222,376. The insider retains substantial holdings of 63,198 shares plus 45,036 derivative securities. The sale is routine equity compensation management and not indicative of concern, as the company demonstrates strong commercial momentum with Q1 product revenue of $225.6 million, driven by PKU drug Sephience's $124.6 million in sales (up 36% quarterly). Management raised full-year product revenue guidance to $750-850 million.
Royalty Pharma acquired the final portion of PTC Therapeutics' royalty on Roche's Evrysdi for $240 million upfront plus up to $60 million in milestones, giving it 100% ownership of the 8-16% tiered royalty. Evrysdi generated $1.9 billion in 2024 sales with projected growth to $2.9 billion by 2030. RPRX stock is up 53% year-to-date but down slightly on Wednesday. The company also recently acquired royalty interests in Nuvalent's cancer drugs.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.